Donaldson Capital Management LLC Sells 5,474 Shares of Novo Nordisk A/S (NYSE:NVO)

Donaldson Capital Management LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,487 shares of the company's stock after selling 5,474 shares during the quarter. Donaldson Capital Management LLC's holdings in Novo Nordisk A/S were worth $2,192,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NVO. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Albion Financial Group UT increased its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after buying an additional 278 shares during the period. Finally, Sound Income Strategies LLC increased its stake in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after buying an additional 243 shares during the period. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $145.25.

Remove Ads

Novo Nordisk A/S Stock Down 1.0 %

Novo Nordisk A/S stock traded down $0.82 during mid-day trading on Tuesday, hitting $78.14. The company had a trading volume of 7,426,424 shares, compared to its average volume of 5,357,347. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock's 50 day moving average price is $84.61 and its two-hundred day moving average price is $104.04. Novo Nordisk A/S has a 12 month low of $77.02 and a 12 month high of $148.15. The company has a market capitalization of $350.63 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.